



29 January 2016

ASX ANNOUNCEMENT

APPENDIX 4C – Quarter Ended 31 December 2015

Brisbane, Australia - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today released its Appendix 4C – Quarterly cash flow report for the period ended 31 December 2015.

Total revenue for the quarter was \$1.2 million, including lymphoedema sales of \$0.7 million. Operating cash outflow for the quarter was \$4.3 million. Cash receipts from customers for the quarter were \$1.3 million and cash on hand as of 31 December 2015 was \$25.2 million.

Highlights for the past quarter include:

- Commenced full US commercial launch of L-Dex for lymphoedema, scale up of sales and clinical support team completed;
- Lymphoedema included in the first American Cancer Society (ACS) / American Society of Clinical Oncology (OCS) Breast Cancer Survivorship Care guidelines;
- Acquired key assets and intellectual property from Intersection Medical Incorporated related to the field of chronic heart failure;
- Agreement established with prestigious Harvard Clinical Research Institute, Dr. Laura Mauri, MD, MSc, Chief Scientific Adviser, on how to best incorporate BIS in fluid monitoring and management of chronic heart failure patients.

“The progress we have made this quarter, has been critical in laying the foundation for the next phase for ImpediMed. With the full commercial launch of L-Dex now underway in the US, and continued recognition of the need for early detection and management of lymphedema, we are well positioned to drive and accelerate the market adoption of L-Dex.”

“In parallel, and following the acquisition of the rights and interests to the technology and IP for BIS in chronic heart failure, we are also embarking on our strategy to pursue other indications. We are very excited about the prospects for ImpediMed in expanding into other indications such as chronic heart failure”, stated Managing Director and CEO, Richard Carreon.

- ENDS -

Richard Carreon
Managing Director & CEO

For further information contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

For personal use only

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

For more information, visit: www.impedimed.com.au

For personal use only

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

ImpediMed Limited

ABN

65 089 705 144

Quarter ended ("current quarter")

31 December 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter	Year to date (six months)
	\$A'000	\$A'000
1.1 Receipts from customers	1,327	2,863
1.2 Payments for (a) staff costs	(2,753)	(6,387)
(b) advertising and marketing	(127)	(345)
(c) research and development	(361)	(884)
(d) leased assets	(6)	(12)
(e) other working capital	(2,382)	(4,398)
1.3 Dividends received	0	0
1.4 Interest and other items of a similar nature received	11	28
1.5 Interest and other costs of finance paid	0	0
1.6 Income taxes paid	0	0
1.7 Other (provide details if material)	0	0
Net operating cash flows	(4,291)	(9,135)

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter	Year to date (six months)
	\$A'000	\$A'000
1.8 Net operating cash flows (carried forward)	(4,291)	(9,135)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	(30)	(32)
(e) other non-current assets	0	0
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	0	0
(e) other non-current assets	0	0
1.11 Loans to other entities	0	0
1.12 Loans repaid by other entities	0	0
1.13 Other (provide details if material)	0	0
Net investing cash flows	(30)	(32)
1.14 Total operating and investing cash flows	(4,321)	(9,167)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	205	250
1.16 Release of restricted cash	0	0
1.17 Proceeds from borrowings	0	0
1.18 Repayment of borrowings	0	0
1.19 Dividends paid	0	0
1.20 Other (provide details if material)	0	0
Net financing cash flows	205	250
Net increase (decrease) in cash held	(4,116)	(8,917)
1.21 Cash at beginning of quarter/year to date	30,374	32,582
1.22 Exchange rate adjustments to item 1.20	(1,106)	1,487
1.23 Cash at end of quarter	25,152	25,152

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	121
1.25	Aggregate amount of loans to the parties included in item 1.11	0

1.26 Explanation necessary for an understanding of the transactions

Item 1.24: Payments to directors consist of Directors' salaries and superannuation and Directors' fees for the quarter and year-to-date. These figures include only Non-Executive Directors and exclude Directors' salaries and Directors' fees that were accrued and unpaid as at the end of the quarter. At 31 December 2015 there were \$35,000 fees accrued and unpaid.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	---	---
3.2	Credit standby arrangements	---	---

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter	Previous quarter
	\$A'000	\$A'000
4.1 Cash on hand and at bank	25,152	30,374
4.2 Deposits at call	0	0
4.3 Bank overdraft	0	0
4.4 Other (provide details)	0	0
Total: cash at end of quarter (item 1.23)	25,152	30,374

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration	N/A	N/A
5.3 Consideration for acquisition or disposal	N/A	N/A
5.4 Total net assets	N/A	N/A
5.5 Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



Date:

29 January 2016

Print name: Morten Vigeland
Chief Financial Officer

+ See chapter 19 for defined terms.

For personal use only

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.

For personal use only